Top Markets
#1 MowCat MowCat +48.90%
#2 Bermuda Shorts Bermuda Shorts +35.34%
#3 aPriori aPriori +23.54%
#4 Derive Derive +19.62%
#5 Velvet Velvet +19.35%
#6 Biconomy Biconomy +19.15%
#7 Audiera Audiera +17.60%
#8 Quack AI Quack AI +17.21%
#9 Perle Perle +15.57%
#10 Block Street Block Street +11.88%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
Rank in Stocks #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Share Price
$0.108
Last synced: 2023-01-23
Market Cap
$4.56M
Change (1 day)
-10.00%
Change (1 year)
0.00%
Country
US
Trade Tricida, Inc. (TCDA)

Category

Healthcare
Revenue for Tricida, Inc. (TCDA)
Revenue in Aug 2026 TTM: 0
According to Tricida, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Tricida, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE